Revenue
2017
2019
2020
2021
2022
2023
2024
2025
KALA BIO, Inc. (KALA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M | $6.4M | $6.1M | — | $0 | $0 | $45,000 |
| Research & development | $18.8M | $22.1M | $18.6M | $17.7M | $11.5M | $18.4M | $27.3M | $29.3M | $29.0M | $25.0M | $11.4M |
| Operating expenses | $39.2M | $41.0M | $39.7M | $85.6M | $141.5M | $102.6M | $94.3M | $64.7M | $39.9M | $32.7M | $16.0M |
| Operating income | −$39.2M | −$41.0M | −$39.7M | −$81.7M | −$130.2M | −$96.2M | −$88.2M | −$64.7M | −$39.9M | −$32.7M | −$15.9M |
| EBITDAderived | −$38.8M | −$40.7M | −$39.4M | −$81.2M | −$129.3M | −$95.3M | −$87.4M | — | — | — | — |
| Net income | −$27.0M | −$38.5M | −$42.2M | −$44.8M | −$142.6M | −$104.3M | −$94.3M | −$66.7M | −$42.2M | −$33.2M | −$16.7M |
| Basic EPSper diluted share | -$3.31 | -$10.15 | -$17.35 | -$29.48 | -$108.32 | -$1.99 | -$2.76 | -$2.49 | -$3.71 | -$28.07 | -$14.89 |
| Diluted EPSper diluted share | -$3.31 | -$10.15 | -$17.35 | -$29.48 | -$108.32 | -$1.99 | -$2.76 | -$2.49 | -$3.71 | -$28.07 | -$14.89 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 23, 2025Form 4 | Reumuth MaryCHIEF FINANCIAL OFFICER | SellCommon Stock | 967 | $0.82 | $792.94 | 28.9K |
| Oct 23, 2025Form 4 | Iwicki Mark TDirector | SellCommon Stock | 154.9K | $0.81 | $125.5K | 103.5K |
| Oct 22, 2025Form 4 | Kharabi DariusCHIEF BUSINESS OFFICER | SellCommon Stock | 20.8K | $0.83 | $17.3K | 41.8K |
| Oct 22, 2025Form 4 | Reumuth MaryCHIEF FINANCIAL OFFICER | SellCommon Stock | 32.2K | $0.83 | $26.8K | 29.9K |
| Oct 22, 2025Form 4 | Bazemore ToddDirector | SellCommon Stock | 47.8K | $0.83 | $39.6K | 35.9K |